The FDA Hearing Almost Nobody Is Preparing For — and Why Your Comment Window Closes October 5, 2026

On September 14, 2026, the FDA will hold a public hearing on the future therapeutic use of psychedelic drugs. It is a four-hour hybrid session at the agency’s White Oak campus, and if you work anywhere in this field — running a clinic, training facilitators, building a service model, or advising people who do — it is the most consequential four hours on the calendar this year.

Here is the part that matters most, and the part I keep finding people do not know: the written comment period stays open until October 5, 2026. The deadline to request a speaking slot passed on August 21. The deadline to put your operational experience into the federal record has not.

That distinction is worth real money to the right operator, and I want to explain why.

Update — September 11, 2026

In the week before the hearing, four FDA officials published a commentary in the New England Journal of Medicine setting out what the agency calls its “new framework for psychedelic drugs.” The authors are Mike Davis, Director of the Center for Drug Evaluation and Research; Tiffany Farchione, Director of the Division of Psychiatry; Bernard Fischer, that division’s Deputy Director; and Teresa Buracchio, Director of the Office of Neuroscience.

The commentary breaks little new regulatory ground. It reviews the mental health crisis, the arc of psychedelic research, and the tools the agency already offers — Breakthrough Therapy designation, and the rolling and priority review that designation makes available. It notes that the July 2026 final guidance reflects roughly two hundred public comments on the 2023 draft.

What matters is the posture. The agency writes that it “is committed to meeting this moment with the urgency it deserves,” and that “[o]ne potential avenue for the development of better treatments includes psychedelic compounds.” It then adds the sentence operators should read twice: “Despite this promise, psychedelic therapies remain investigational, and our approach to integrating these complex programs into existing regulatory frameworks is still evolving.”

Four senior officials chose to say that, in that venue, days before a public hearing. Read it as confirmation that the agency intends to keep engaging with this field — and as the agency’s own statement that the framework is not settled. Both readings argue for the same thing: put your operational experience in the record before October 5.

Citation: Davis M, Farchione T, Fischer B, Buracchio T. FDA’s New Framework for Psychedelic Drugs. N Engl J Med. September 2026. doi:10.1056/NEJMsb2609286.

What the hearing actually is

The FDA published notice of the hearing in the Federal Register on July 14, 2026, under Docket No. FDA-2026-N-7542. The hearing itself runs September 14, 2026, from 12:30 p.m. to 4:30 p.m. Eastern, in person at White Oak and virtually.

The agency’s own framing is narrow and deliberate. From the notice: the FDA is holding the hearing “to obtain feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings.”

Four topic areas are on the table:

Provider training and credentialing — who is qualified to sit with a patient during a session, and what proves it
Promotion of patient safety — screening, informed consent, adverse event monitoring
Considerations for access — how patients actually reach these treatments
Best practices for data collection and standardization

Why the comment record is the real opportunity

Regulatory comment periods look like civics homework. They are not. They are the record an agency builds a rule on, and they are the record a court later reviews.

Three of the four topic areas above — training and credentialing, safety practices, and access — are precisely the areas where a future REMS (Risk Evaluation and Mitigation Strategy, the FDA’s mechanism for imposing conditions on how a risky drug is distributed and administered) would live. A REMS is where the abstract question “who may administer this?” becomes a concrete, binding answer that determines whether your clinic model is viable or obsolete.

The FDA has already signaled where its thinking sits. In July 2026 the agency finalized its guidance document Psychedelic Drugs: Considerations for Clinical Investigations (Federal Register notice July 14, 2026, Docket No. FDA-2023-D-1987), three years after issuing it in draft. Among other things, the final guidance calls for “[o]bservation by two monitors for the duration of the treatment session,” with a lead monitor who is “a health care provider with graduate-level professional training and clinical experience in psychotherapy, licensed to practice independently,” and an assistant monitor holding at least a nursing or bachelor’s degree with a year of clinical experience in a licensed mental health setting.

That is a trial-conduct standard, not a practice standard. But trial-conduct standards have a way of becoming the template for post-approval conditions. If a two-monitor model with an independently licensed lead becomes the price of admission, that reshapes staffing costs, physical plant requirements, and unit economics for every service model in the country.

The guidance also does something quieter that operators should read carefully. It states that “the contribution of the psychotherapy component to any efficacy observed with psychedelic drug treatment has not been characterized,” and suggests factorial trial designs to separate drug effect from therapy effect. Whether the therapy is part of the treatment or adjacent to it is not an academic question. It determines who can bill for it, who must be licensed to deliver it, and whether it falls inside or outside a drug’s approved labeling.

What a useful comment looks like

Most comments filed in dockets like this are position statements. Position statements are the least useful thing you can file, because the agency already knows the positions.

What agencies are short on is operational fact. If you run a ketamine practice, a research site, or a training program, you have data no one at White Oak has:

What your actual staffing ratios are, and what they cost per session
What your screening protocol catches, and what it has missed
How long a session genuinely occupies a room and a clinician, including the tail
What your adverse event rate looks like and how you define an adverse event
Where your informed consent process breaks down in practice
What credentialing standard you actually apply when you hire, and why

File that. Anonymize it if you must, and be careful about anything patient-identifying, but file it. A comment that says “the two-monitor requirement will impose a 40% increase in per-session labor cost, which at our volume translates to X” is a comment that gets read. A comment that says “we support access” is not.

Practical note on confidentiality: comments filed in a public docket are public. If your operational data is competitively sensitive, the FDA’s docket system has a procedure for confidential submissions, and you should use counsel to structure that rather than improvising. Do not put anything in a public docket that you would not want a competitor, a plaintiff’s lawyer, or a state licensing board to read.

What is not happening, despite what you may have heard

I want to be direct about the current state of federal law, because there is a great deal of enthusiastic misreporting in this space and some of it is being repeated by people who should know better.

No psychedelic drug has been approved by the FDA. As of today, none. Compass Pathways is submitting its COMP360 psilocybin application for treatment-resistant depression on a rolling basis and has publicly stated it expects to complete that submission in the fourth quarter of 2026. No PDUFA goal date has been announced. The company’s own stated launch target is the first half of 2027, and it has said that target is contingent on approval and on federal and state rescheduling.

Right to Try does not currently provide a psychedelic access pathway. Executive Order 14401 directs the FDA and DEA to establish one, including for ibogaine compounds. No implementing document exists — no FDA guidance, no DEA rule, no Federal Register notice. As a practical matter, federal Right to Try also requires a drug that has completed a Phase 1 trial, and the first U.S. IND for an ibogaine derivative (noribogaine, for alcohol use disorder) was only authorized in April 2026. If someone is telling you that patients can access psychedelics today under Right to Try, they are wrong, and building a business on that premise is a serious mistake.

Psilocybin has not been rescheduled. A psilocybin rescheduling petition has been pending at the DEA for years. There is no DEA notice of proposed rulemaking and no published HHS scientific recommendation. The correct description is “no action taken,” not “denied” and certainly not “in progress.”

What I would do this month

If you are an operator or a clinician in this field, three things:

Calendar October 5. Draft your comment now, while the hearing is fresh, and file before the deadline. Docket No. FDA-2026-N-7542.
Read the final guidance against your own operating model. Not for compliance today — it does not bind you today — but as a forecast of what post-approval conditions may look like. Where you are already aligned, document it. Where you are not, understand what it would cost to get there.
Stop treating approval as the finish line. It is not, and the next post in this series walks through the five separate legal gates that stand between an FDA approval and a patient in a California treatment room. Approval is the first one, and it is not the hardest.

If you would like to talk through how any of this maps onto your specific structure, I am happy to do that. This is a field where the general answer and the answer for your entity are frequently different.

Deja A. Correia, Esq. | The Correia Law Firm | San Diego, California

This post is general information about publicly available legal and regulatory developments. It is not legal advice, it does not create an attorney-client relationship, and it should not be relied on as a substitute for advice about your specific situation. Regulatory positions in this area are changing quickly; verify current status before acting.